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Abstract
Hepatitis B virus envelope glycoproteins Large (L), Middle (M) and Small (S) are targets of the host cellular immune system.
The extent to which the host recognizes viral antigens presented by infected cells is believed to play a decisive role in
determining if an infection will be resolved or become chronic. As with other antigens, HBV envelope polypeptides must be
degraded, presumably by cellular proteasomes, to be presented by the MHC I pathway. We have used M as a model to
study this process and determine how ER quality control monitors these foreign polymeric proteins and disposes of them
through the ER-associated degradation (ERAD) pathway. Using both wild type and mutant HBV M protein, we found that
unlike most ERAD substrates, which require ubiquitination for retrotranslocation and degradation, the HBV M protein, which
only contains two lysine residues, can undergo rapid and complete, ubiquitin independent, proteasome dependent
degradation. The utilization of this pathway had a functional consequence, since proteins degraded through it, were poorly
presented via MHC I. To test the hypothesis that the level of ubiquitination, independent of protein degradation, controls
the level of antigen presentation, we inserted two additional lysines into both the wild type and mutant M protein.
Amazingly, while the addition of the lysine residues dramatically increased the level of ubiquitination, it did not alter the
rate of degradation. However and remarkably, the increased ubiquitination was associated with a dramatic increase in the
level of antigen presentation. In conclusion, using the HBV surface protein as a model, we have identified a novel ubiquitin
independent degradation pathway and determined that this pathway can have implications for antigen presentation and
potentially viral pathogenesis.
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Introduction
Newly synthesized secretory and membrane proteins are
translocated into the endoplasmic reticulum (ER) co-translation-
ally, where they undergo folding and post-translational modifica-
tion including N-linked glycosylation before delivery into the
secretory pathway [1–5]. Proteins that fail to fold correctly or take
too long to fold are extracted from the folding cycle by the ER
quality control (ERQC) machinery [6]. This cellular function
ensures that only polypeptides that attain their native conforma-
tion can reach their final destinations and monitors any terminal
misfolded proteins to be retrotranslocated out of ER and degraded
by the 26S cytosolic proteasome in a series of tightly regulated
processes, referred to as the ER-associated degradation (ERAD)
pathway [1,7]. The end result of this pathway is the controlled
degradation of misfolded proteins and the generation of peptides
for MHC I antigen presentation [8]. Ubiquitination is thought to
play an essential role in both the dislocation and proteasomal
degradation of misfolded ER associated proteins [9–13].
Hepatitis B virus (HBV) specifies three envelope glycoproteins,
called large (L), middle (M), and small (S), that are all derived from
the same open reading frame (ORF). These proteins are
synthesized and translocated into the ER where they undergo
folding and potentially N-linked glycosylation before secretion
through the trans-Golgi network. The M protein differs from the
other HBV envelope proteins in that while the L and S proteins
are made and secreted in unglycosylated or N-glycosylated forms
[14], the M protein is always secreted as a singly (gp33) or doubly
(gp36) glycosylated species. An unglycosylated M species (p30) is
found within the cell but the nature and fate of this molecule has,
until now, remained a mystery [15].
HBV infection can lead to either an acute or a chronic infection.
Whether or not the infection is resolved is believed to depend upon
the extent to which host T lymphocytes recognize and clear HBV
antigen presenting hepatocytes. To study the pathway of
degradation (and presentation) of the HBV envelope proteins,
the HBV M protein was employed as a model to study how ER
quality control monitors and disposes of secretion incompetent
PLoS ONE | www.plosone.org 1 September 2011 | Volume 6 | Issue 9 | e24477HBV surface proteins through the ERAD pathway. The HBV M
protein was chosen as it can be expressed and secreted
independently of the other proteins and mutations within it are
often associated with pathology [16–25]. We found that wild type
M protein along with a secretion incompetent M protein mutant
[26] could be efficiently retrotranslocated from the ER and
degraded via the cytosolic proteasome independent of ubiquitina-
tion. Furthermore the utilization of this ubiquitin independent
pathway was associated with poor antigen presentation as both
wild type and mutant M proteins were poorly presented via MHC
I regardless of their rate of proteasomal degradation. Forcing
ubiquitination through the addition of two lysine residues resulted
in increased antigen presentation without altering the rate of
protein degradation. Therefore, using the HBV M protein as a
model, a novel ubiquitination independent, proteasome dependent
ERAD pathway was discovered. Functionally, a virus such as
HBV may utilize this pathway to limit antigen presentation.
Results
The HBV M protein does not require ubiquitination for
entry into ERAD pathway
In our previous work examining the folding and degradation of
the HBV envelope proteins we noticed that the HBV middle (M),
and small (S) envelope glycoproteins, similar to many toxins, have
only one or two potential sites of ubiquitin conjugation (lysine
residues) [27,28]. As these toxins can co-opt the ubiquitin-
independent retrotranslocation machinery to induce pathology
[27,28], we hypothesized that the removal of misfolded HBV M
and S envelope glycoproteins from the ER may occur in a
ubiquitin independent manner as well. To test this hypothesis, we
examined the degradation of the W/T M protein and a mutant M
protein in which the two potential sites of ubiquitination
conjugation were altered (K141A and K160A) to prevent lysine
mediated ubiquitin conjugation. As shown in Figure 1A, expres-
sion of the HBV M protein results in the intracellular
accumulation of three bands, which correspond to the unglyco-
sylated or potentially de-glycosylated M protein (p30) [29], a singly
glycosylated M protein (gp33) and a doubly glycosylated M protein
(gp36). When cells are treated for 16 hours with the proteasome
inhibitor epoxomicin, there is primarily an increase in the
unglycosylated (p30) form of the M protein (Figure 1A, lane 1
and 2) with smaller increases in the gp33 and gp36 M bands.
Similar increases are also seen with full length HBV producing cell
lines such as Hep G2 2.215 cells (Figure S1). There are three
explanations for this. The first is that the p30 species is an M
protein that fails to enter the ER (hence is not glycosylated) and is
degraded in a non ER mediated proteasome dependent manner.
The second possibility is that the p30 M protein is an
unglycosylated M species that fails quality control within the ER
and is retrotranslocated into the cytosol for proteasome mediated
degradation. The third possibility is that the p30 M isoform is the
Figure 1. Lysine linked ubiquitination is not required in the proteasome dependent degradation of the HBV M protein. (A) In order
to test the hypothesis that ubiquitination is not important for the targeting of W/T M protein for proteasome dependent degradation, K141 and K160
on wild type M (MS) was mutated to Alanine (MSKA). The constructs were transfected into 293T cells and either left untreated (-) or treated with
proteasome inhibitor epoxomicin (1.5 uM) for 16 h. The cells were then lysed and the intracellular M protein detected via immunoblot using a PreS2
antibody (a.a.13–26 of PreS2). The locations of the three species of wild type M protein are indicated. The asterisk is used to highlight the p30, which
accumulate with proteasome inhibition. The level of b-actin was used to monitor loading and is shown below the M immunoblot. (B) The p30, gp33
and gp36 M proteins are ERAD substrates. MS (left) or MSKA (right) were either co-transfected into 293T cells with an empty vector, or a dominant
negative P97 (P97QQ) expression vector and the level of M protein (for Pre-S2 domain), p97 and actin measured by immunoblot. Anti-PreS2
immunoblot shows that inhibition of functional P97 by over expression of dominant negative P97 rescued all of the transfected contructs, indicating
that p97 is required for the degradation of the HBV M protein in a ubiquitin indepedent manner. (C) Removal of lysine residues indeed blocks
ubiquitination of W/T M protein. HEK293T cells were either transfected with HA-Ub alone or cotransfected with MS or MSKA as indicated and left
untreated or treated with the proteasome inhibitor Lactacystin (20 uM) for 16 hours. Anti-HA and anti-PreS2 immunoblots were used confirm the
expression of each indicated protein. Co-immunoprecipitation was performed using HA affinity gel followed by western blot analysis with anti-PreS2
antibody to detect interaction between HA-tagged ubiquitin and wild type or mutant M proteins. Regardless of the presence of lysine residues
(compare MS and MSKA), HA-tagged ubiquitin could not be detected on wild type M protein, confirming the lack of ubiquitin conjugation.
doi:10.1371/journal.pone.0024477.g001
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degradation by the cytosolic proteasome [29]. That is, the glycans
on retrotranslocated glycoproteins are removed in the cytosol by
the action of a cytosolic PnGase F before proteasomal degradation
[30]. To determine the nature of the p30 species we utilized a
dominant negative Cdc48/P97 expression vector to determine the
intracellular origin of the p30 M isoform. The cytoplasmic ATPase
Cdc48/P97 complex plays a key role in the retrotranslocation of
ERAD substrates from the ER through ATP hydrolysis. When this
dominant negative variant is expressed, proteins that utilize
Cdc48/P97 for retro-translocation will accumulate within the
ER [31] before the action of the cytosolic PnGase F. Thus, to
determine the nature of the p30 M protein, wild-type M protein
was transfected either with a shuttle vector (Figure 1B, Lanes 1) or
cotransfected with a dominant negative P97 (P97QQ) construct
(Figure 1B, Lane 2) [32]. It is noted that while p97 could be
detected in all cells, no increases in total p97 was observed when
p97QQ was expressed, which is consistent with other reports using
this p97 dominant negative construct [32]. Figure 1B shows that
when the function of endogenous P97 was inhibited by P97QQ in
cells co-transfected with the M expression vectors, accumulation of
the gp36, gp33 and p30 isoforms occurred (Figure 1B, lane 1 and
2). This indicates that all three of these proteins are ERAD
substrates and importantly, indicates that the p30 species seen
after proteasome inhibition (Figure 1A, lane 2) is the result both of
the de-glycosylation of gp33 and gp36 that fails ER quality control
and the ERAD of unglycosylated M protein (p30).
Figure 1A also shows that, consistent with the original
hypothesis, the alteration of lysines at position 141 and 160 did
not result in any substantial increase in any form of the M protein,
suggesting that lysine linked ubiquitination is not required for
efficient degradation of the M protein (Figure 1A lane 1 and 3). In
contrast, similar to what was observed with wild type M protein,
treatment with epoxomicin (Figure 1A lanes 3 and 4) lead to an
increase in the p30 form of the M protein suggesting that this
protein is still degraded via the cytosolic proteasome. In addition,
inhibition of ERAD through the use of the p97 dominant negative
mutant leads to the accumulation of the same M bands as were
observed with the wild type M protein (Figure 1B lane 4, implying
that the wild type and lysine negative mutants are degraded in a
similar way.
In order to ensure that removing the two-lysine residues
completely blocked the ubiquitination of the M protein, a Co-IP
was performed to detect whether HA-tagged ubiquitin could be
conjugated to either the wild type or the lysine-free mutant in the
presence of the proteasome inhibitor Lactacystin [33]. Results
shown in Figure 1C indicate that WT M is not ubiquitinated with
the HA-tagged ubiquitin as it cannot be immunoprecipitated using
HA affinity gel immunoprecipitation. This is true regardless of
whether the lysine residues were present or not (right panel of
Figure 1C). Thus in conjunction with the above results, the W/T
M protein appears to be efficiently degraded via a ubiquitin
independent but proteasome dependent manner.
Secretion incompetent HBV envelope protein mutants
also do not require ubiquitination for proteasome
dependent degradation
Although the results in Figure 1 clearly indicated that the wild
type M protein does not require ubiquitination for degradation
through the proteasome complex, the overall level of protein
degradation was limited. Thus we examined a secretion
incompetent M (and S) protein mutant [26] in an effort to
determine if a more unstable protein could also utilize this
pathway. Cysteine residues C48, 65 and 69, which are all involved
in M protein inter-chain disulfide bond formation [26], were
changed to alanines, and the expression construct was named as
CA. The CA M expressing construct was transfected into 293T
cells and the rate of CA M protein degradation was determined by
treatment with the proteasome inhibitor epoxomicin. As shown in
Figure 2A, the steady state levels of the CA M protein were much
lower than wild type unless epoxomicin was included in the cell
culture medium, suggesting that CA M protein is rapidly degraded
by the cytosolic proteasome. The CAKA mutant, made by
changing all the lysine residues in CA to alanines, was also rapidly
degraded by the proteasome (compare lanes 5 and 6). Indeed, the
levels of the CA and CAKA M protein were identical, regardless of
the presence of lysine residues and presumably ubiquitin
conjugation (compare lanes 3 and 5). Similar to the wild type M
protein that failed ER quality control, Figure 2B shows that when
the function of endogenous P97 was inhibited by overexpressing
the dominant negative form of P97 (P97QQ), the CA (Figure 2B)
mutant dramatically accumulated, as compared with the cells in
which only functional P97 (wild-type P97) was present. Similar to
the results in Figure 1B, all three CA M isoforms accumulate again
implying that these isoforms fail ER quality control (similar to the
wild type) and are sent out of the ER for degradation by the
cytosolic proteasome. The overexpression of P97QQ could also
rescue the nonubiquitinated CA M mutant substrates (CAKA)
suggesting that both the wild-type M protein and the CA mutant
can enter an ubiquitination-independent, P97-dependent, protea-
some-dependent ERAD degradation pathway.
In order to ensure that removing the two-lysine residues
completely blocked the ubiquitination of CA, a Co-IP was
performed to detect whether HA-tagged ubiquitin could be
conjugated to the lysine-free CAKA mutant in the presence of
the proteasome inhibitor Lactacystin. In the absence of protea-
some inhibition, very limited CA M protein is observed (see
figure 2A), hence proteasome inhibition was used to allow for
accumulation of protein. Thus the CA M protein observed in the
middle panel of Figure 2C represents that CA M protein which is
to be degraded by the proteasome. While the results shown in
Figure 1C indicate that WT M is not ubiquitinated, a small level of
HA-tagged ubiquitin was found to be associated with the CA M
protein (Figure 2C). That is, in the CA M protein that contains
lysine residues, low levels of HA-tagged polyubiquitinated CA M
protein could be detected as a ladder (smear) that was present in
cells producing both HA-tagged ubiquitin and the HBV CA
protein, which was not present in cells producing just HA tagged
ubiquitin (Figure 2C). It is noted that the level is low and much
lower than what is observed with other ubiquitinated proteins
(shown below). In addition, no evidence of ubiquitination was
observed on the CAKA M mutant (Figure 2C) indicates that
ubiquitin conjugation was not required for the efficient degrada-
tion of this secretion incompetent misfolded M protein. Inhibitors
of lysosomal degradation had no impact upon the levels of either
wild type or CA mutant, indicating no role for non proteasomal
pathways in the degradation of the HBV M protein (Figure S2).
Role of N-linked glycan in the degradation of HBV
envelope proteins
The ERAD pathway involves a set of lectin-like proteins that
are involved in substrate recognition and targeting of misfolded
protein for ERAD [34]. The ER degradation-enhancing a-
mannosidase-like protein (EDEM) is thought to associate with
misfolded glycoproteins that have failed the deglycosylation–
reglycosylation cycle and have been processed by ER mannosidase
I. Similarly, the mammalian homologues of yeast osteosarcoma 9
(OS-9) are thought to bind to glycoproteins processed by the ER
Ubiquitin Independent Degradation of HBV Proteins
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residues.
The role of EDEM and OS-9 was tested either by removing the
two (ASN-4 and ASN-146) potential sites of glycosylation on the
CA mutant (Figure 3A) or by coimmunoprecipitation studies with
EDEM (Figure 3B) or OS-9 (Figure 3C) overexpression vectors. As
Figure 3A shows, removal of all glycosylation sites on either the
CA mutant or the CAKA mutant had no impact on the level of
degradation, implying that the glycans do not play a role in the
degradation of these proteins.
We further examined whether EDEM and OS-9 were associated
in the degradation of these proteins following cotransfection with
the CA mutant. As a control, the null Hong Kong variant of a1-
antitrypsin (NHK) was used because it was previously shown to
interact with both EDEM and OS-9 [35]. Figure 3B shows that
although NHK could be coprecipitated with EDEM, no interaction
was observed with the CA mutant, indicating that the M protein is
degraded in an EDEM-independent manner.
The role of two major isoforms of OS-9 was examined in a way
similar as to EDEM. As Figure 3C shows, although the NHK
variant was able to interact with both OS-9.1 and OS-9.2, no
interaction was observed with the CA mutant, suggesting no role
for these chaperone-like proteins, and potentially the N-linked
glycans, in the recognition and degradation of the HBV envelope
proteins.
Ubiquitination, independent of protein degradation, is
essential for efficient antigen presentation of the HBV
envelope proteins
Ubiquitination is often associated with enhanced protein
degradation and subsequent antigen presentation via the MHC I
pathway [8,36,37] and a recent report has indicated that
ubiquitination was essential for presentation of ER associated
antigens [38]. As we did not observe substantial ubiquitin
dependent degradation of the HBV envelope proteins, it was of
interest to determine if the utilization of this pathway affected
antigen presentation. To determine this, we examined the level of
antigen presentation of the W/T and CA mutant using an in vitro
antigen presentation system. In addition, we modified both the W/
T and CA mutant to contain two additional lysine residues, in an
effort to determine if we could get increased levels of ubiquitination
Figure 2. Secretion incompetent M protein is rapidly degraded through an ubiquitination independent, proteasome dependent
pathway. (A) Cys-48, Cys-65 and Cys-69 on wild type M protein was converted to Alanines, and the construct was named as CA. In order to study the
role of ubiquitination in the rapid degradation of the CA mutant protein, all the lysine residues (K141, K160) were mutated to Alanines, and the
construct was named as CAKA. Wild type M construct (MS), CA and CAKA were transfected into 293T cells and either left untreated (-) or treated with
epoxomicin for 16 hours one day post-transfection. The accumulation of CA mutant protein in the presence of the proteasome inhibitor implies that
this protein is being degraded in a proteasome dependent manner; however this degradation process does not require ubiquitination as removal of
Lysines did not prevent the rapid degradation by the proteasome. The level of b-actin was used to monitor loading and shown below the M
immunoblot (B) The p30, gp33 and gp36 CA M proteins are ERAD substrates. CA and CAKA were either co-transfected into 293T cells with an empty
vector, or a dominant negative P97 (P97QQ) expression vector and the level of M protein (for Pre-S2 domain), p97 and actin measured by
immunoblot. Anti-PreS2 immunoblot shows that inhibition of functional P97 by over expression of dominant negative P97 rescued all of the
transfected contructs, indicating that p97 is required for the degradation of the HBV M protein in a ubiquitin indepedent manner. (C) Removal of
lysine residues indeed blocks ubiquitination of CA. HEK293T cells were either transfected with HA-Ub alone or cotransfected with CA or CAKA as
indicated, and either left untreated or treated with the proteasome inhibitor Lactacystin (20 uM) for 16 hours. As in Figure 2, anti-HA and anti-PreS2
immunoblots were used to confirm the expression of each indicated protein. However, when lysine residues were removed (CAKA), none of the
ubiquitinated misfolded M could be detected as there is no any specific signal comparing to the control lane in which HA-Ub alone was transfected in
the cells, indicating that removal of Lysine residues indeed prevents ubiquitination of CA mutant proteins.
doi:10.1371/journal.pone.0024477.g002
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arginines at positions 73 and 122 were converted to lysines as these
positions contain lysines in other HBV genotypes (as opposed to
lysines at position 141 and 160) and these two mutants are referred
to as MSK4 and CAK4 (Figure 4A). As an initial test, we
determined if ubiquitination could be observed on the MSK4 or the
CAK4 mutant. This was done using the same method as in
Figures 1C and 2C. As Figure 4B shows, while ubiquitination could
not be observed on the MS, or CA constructs, ubiquitination, in the
form of a ladder were observed on the MSK4 and CAK4 proteins
(Figure 4B, bottom panel). The CAK4 had dramatically increased
levels of ubiquitination, presumably as a result of the greater rate of
degradation of this protein.
Ubiquitination is thought to enhance antigen presentation
through increased proteasomal degradation [39,40]. The relative
stability of CAK4 was compared to the parental CA mutant
following transfection into Hep G2 cells and the level of the M
protein found in cell lysates determined following a 40 minute
pulse with
35S methionine/cysteine and either a 0, 20, 60 or
120 minute chase. As Figure 5A shows, after a 40 minute label
and 20 minute chase, the level of intracellular M protein was
reduced by 50% in both the CA mutant and the CAK4 mutant.
The level of this protein continued to decline and was reduced by
almost 90% at the 120-minute time point. Importantly, the rate of
degradation of the two mutants was equal (Figure 5B).
We next set out to examine the role of ubiquitination in HBV
M protein class I antigen presentation. The wild type (MS and
MSK4) and CA (CA and CAK4) expression vectors were
engineered to contain the H-2K
b-restricted OVA257-264
SIINFEKL epitope at the C- terminus of the M protein (in the
S domain) [41–43]. This class I epitope is a useful tool to
measure antigen presentation and is engineered with flanking
sequences to allow for proper processing and the measurement of
antigen presentation [38,41,44]. These vectors were transfected
into mouse L-K
b cells and the level of antigen presentation
determined using a CTL clone (B3.Z) for the SIINFEKL epitope
[42,43]. As Figure 5C shows, transfection of the MS expression
vector (lacking the SIINFEKL sequence) does not activate the
B3.Z CTL clone and has background levels of luminescence,
similar to mock transfected L-K
b cells. In contrast both the
constructs (MSOVA and CAOVA) containing the OVA
sequence lead to the low level of activation of the B3.Z clone,
suggesting limited levels of antigen presentation. The level of
B3.Z activation (as compared to MS) was not statistically
significant for MSOVA (p=0.46) but was for CAOVA
(p,0.05). However, as shown in Figure 5C both constructs with
the additional lysine residues and enhanced levels of ubiquitina-
tion (MSK4-OVA and CAK4-OVA) had dramatic increases in
the level of OVA peptide presented as compared to wild type
MS-OVA or CA-OVA. The MSK4OVA vector lead to a 4.8
fold increase in B3.Z activation as compared to MSOVA, while
CAK4OVA lead to an 8.6 fold increase (as compared to
CAOVA) (p,0.0001). More importantly, this increased level of
B3.Z activation correlated with the level of ubiquitination
observed in Figure 3. That is, the CAK4 construct, which had
dramatically increased levels of ubiquitination (Figure 3B), had
the greatest level of antigen presentation. Furthermore, this
presentation was proteasome dependent as inhibitors of the
proteasome prevented all antigen presentation (Figure 5C).
To ensure that the results obtained with the OVA tagged M
protein could also be observed with natural HBV epitopes, we
performed a CTL stimulation assay using HBV specific T-cells
and HepG2 cells transfected with the above four HBV expression
vectors [45]. Activation of HBV specific T cells was measured
using an interferon gamma ELI-SPOT assay [45]. As Figure 5D
shows, while weak activation could be observed from the MS and
CA targets, the MSK4 and the CAK4 constructs show
dramatically increased levels (p,0.05) of T-cell stimulation, similar
Figure 3. N-linked glycans and the lectin like proteins EDEM and OS-9 are not involved in the degradation of HBV envelope
proteins. (A) Removal of N-linked glycan sites on CA or CAKA does not affect the degradation of the M protein. (B) The CA mutant does not interact
with EDEM. Either the NHK or CA mutant was transfected alone or together with an EDEM over-expresser into HEK-293 cells and the association
between NHK and EDEM or CA and EDEM determined by either immunoprecipitation of NHK or M protein followed by western blot for EDEM. As this
Figure shows, while EDEM can be immunoprecipitated with NHK, CA can not. (C) The CA mutant does not interact with OS-9.1 or OS-9.2. Similar to
the experiments with EDEM, either the NHK or CA mutant was transfected alone or together with a OS-9.1 or OS-9.2 over-expresser into HEK-293 cells
and the association between NHK and OS-9 or CA and OS-9 determined by either immunoprecipitation of NHK or M protein followed by western blot
for OS-9.
doi:10.1371/journal.pone.0024477.g003
Ubiquitin Independent Degradation of HBV Proteins
PLoS ONE | www.plosone.org 5 September 2011 | Volume 6 | Issue 9 | e24477to what was observed with the OVA tagged constructs. This result
further supports the hypothesis that proteasomal mediated
degradation along with ubiquitination is required for efficient
presentation of M protein following ERAD.
Discussion
To study how the cellular ERAD machinery recognizes and
disposes of aberrant viral envelope proteins, we created a model
system using wild type and secretion incompetent HBV envelope
proteins. In our study we found that surprisingly, ubiquitination
was not an absolute requirement for the degradation process of
either wild type or mutant HBV envelope proteins. Our results
indicate that in cell culture, misfolded mutant forms of HBV
envelope proteins are effectively removed from the ER and
degraded via the proteasome in a ubiquitin independent manner.
This represents the first report of a molecule that is removed from
the ER and degraded by the proteasome in a ubiquitin
independent manner.
Importantly, there is a functional consequence to the utilization
of this ubiquitin independent degradation pathway as both the
wild type and mutant HBV M proteins were associated with
limited MHC I antigen presentation. This was even true of M
protein (the CA mutant) that was highly unstable and was rapidly
degraded through a proteasome dependent manner. Indeed the
wild type M protein and the CA mutant, although they had
dramatically different rates of proteasomal degradation, had the
same low level of antigen presentation in two different assays
(Figure 5). A previous report has indicted that the woodchuck
hepatitis B virus pre-S2 protein (WHBV M protein) could prevent
the MHC I presentation through a reduction of cell surface MHC
molecules [46]. Thus, an attractive hypothesis is that when the M
protein is degraded in a ubiquitin independent manner, it takes
MHC I with it to the proteasome and thus leads to the reduction
of antigen presentation. This was briefly tested by the direct
addition of SIINFEKL peptide to M expressing cells and testing
for B3.Z activity. In such an assay, there was no major difference
in activity between M expressing cells and mock transfected cells.
However, more sensitive assays are required to truly determine the
role of M on the MHC I.
The addition of two extra lysine residues, which resulted in
increased levels of ubiquitination, resulted in increased levels of
antigen presentation for both the wild type, and more impressively
for the CA mutant. Importantly the increase in ubiquitination did
not result in any change in the rate of degradation. Therefore it
appears that ubiquitination, independent of protein degradation, is
important for the efficient presentation of the HBV M and S
envelope proteins. In addition, by limiting the number of lysine
residues on the M and the S proteins, the virus theoretically can
limit the presentation of peptides from these highly abundant
proteins thus providing a selective advantage for the virus. It is
noted that the HBV L protein contains two additional lysine
residues in the Pre-S1 domain and its degradation pathway may
be fundamentally different than that observed with the M protein.
Indeed the expression of the HBV L protein is thought to occur
latter during the natural infection (after the other envelop proteins)
to allow for CCC DNA formation through recycling of the rcDNA
back to the nucleus [47–50]. The level of the L protein controls
this cycle, as it is essential for secretion of enveloped virus.
Recent reports have indicated that the 20S proteasome has been
known to degrade non ubiquitinated proteins (highly inefficiently)
and it is possible that this could impact antigen presentation [51–
53]. Indeed, it has even been suggested that the 20S proteasome
may present peptides from rapidly degraded proteins [51].
However, degradation through the 20S proteasome should still
lead to the production of the SIINFEKL epitope [8], which was
not observed in our case.
It is noted that glycoproteins with low lysine contents can
become ubiquitinated on non lysine residues and thus be efficiently
Figure 4. The introduction of two additional lysine residues
into the M protein increases the levels of ubiquitination. (A)
Two additional lysine residues were introduced at positions 73 (R to K)
and at position 122 (R to K) in both the wild type and CA mutants.
Constructs with additional lysine residues are referred to as MSK4 and
CAK4. (B) Evidence for enhanced ubiquitination was determined using
the HA tagged ubiquitin construct as in Figures 1 and 2. Briefly,
HEK293T cells were either transfected with HA-Ub alone or cotrans-
fected with MS, MSK4, CA or CAK4 constructs as indicated and either
left untreated or treated with the proteasome inhibitor Lactacystin
(20 uM) for 16 hours. Anti-HA and anti-PreS2 immunoblots were used
to confirm the expression of each indicated protein. Co-immunopre-
cipitation was performed using HA affinity gel followed by western blot
analysis with anti-PreS2 antibody to detect interaction between HA-
tagged ubiquitin and wild type or mutant M proteins. While no
ubiquitination can be observed with the MS or CA mutants, increased
ubiquitination can be observed with the MSK4 CAK4 constructs (a
ladder pattern consistent with multi ubiquitination).
doi:10.1371/journal.pone.0024477.g004
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case, when we examined total protein linked ubiquitin conjuga-
tion, it was not observed suggesting that these protein may
undergo ubiquitin independent ERAD.
Thus, this report may represent one of the few examples of a
protein that could be degraded in a ubiquitin independent but
proteasome dependent ERAD pathway [53]. That is, most
polytopic membrane-anchored ERAD substrates, such as the
Cystic Fibrosis Transmembrane Conductance Regulator (CFTR)
protein require ubiquitination catalyzed by the ER membrane
associated E3 ubiquitin ligase. This polyubiquitination has been
seen as an essential step in the retrotranslocation of proteins out of
the ER for degradation by the cytosolic proteasome [55,56].
While polyubiquitination of ERAD substrates seems to be the
general rule, there are several examples of ubiquitin independent
dislocation in ERAD. Yu et al reported in 1997 that removing all
the lysine residues on TCR-a did not change it’s degradation
kinetics, suggesting that ubiquitination was not required for
degradation of TCR-a [57]. However, this study could not provide
definitive evidence that TCR-a mutant completely lacked ubiqui-
tination. Expanding upon these initial results, Yu and Kopito in
1999, inhibited the cellular ubiquitination system, and found that
degradation of TCR-a and KaR was suppressed indicating that
ubiquitination was indeed required for the dislocation and
degradation of TCR-a [12]. Cholera toxin A1, a non-ubiquitinated
substrate, utilizes a retrotranslocation process from the ER into the
cytosol in order to induce toxicity by activating cytosolic cAMP.
However, Cholera toxin A1 is not a typical ERAD substrate and
unlike other misfolded ER proteins and the results presented here,
can escape degradation after a P97 independent dislocation event
Figure 5. Ubiquitination is required for the efficient presentation of the HBV M protein. (A) Ubiquitination does not alter the rate of
degradation of the CA mutant. HepG2 cells transfected with the CA or CAK4 expression construct were pulsed with
35S -Met/Cys for 40 minutes
followed by 0, 20, 60 or 120 minute chase period. M-specific polypeptides were immunoprecipitated using an antibody to amino acids 13–26 of the
pre-S2 domain. The location of the major M protein species is indicated. (B) Quantification of the level of M protein as a function of time of the CA or
CAK4 mutant. (C) An in vitro antigen presentation assay highlights the importance of ubiquitination for presentation of the HBV envelope proteins.
Briefly, the MS, MSK4, CA and CAK4 expression vectors were engineered to contain the H-2 Kb-restricted OVA257-264 SIINFEKL epitope at the C-
terminus of the M protein. Transfection of the MS (non OVA tagged) does not activate the B3.Z CTL clone and hence they produce background levels
of luminescence, similar to mock transfected L-Kb cells. In contrast both the MS OVA and the CA OVA M construct lead to the activation of the B3.Z
clone. However both the MSK4 OVA and CAK4 OVA constructs lead to statistically significant (p,0.05 for MSK4 and P,0.0001 for CAK4) increases in
the level of CTL activation, as compared to the MS or CA Ova constructs. (D) PBMCs isolated from healthy HLA-A2+ human donor blood were
stimulated in vitro with peptides corresponding to the HLA-A2–restricted CTL epitope from HBs (FLLTRILTI) The ability of in vitro–generated CTLs to
recognize and secrete interferon-c (IFNc) was evaluated by ELI-Spot assay. The number of IFN producing cells reactive to MS, MSK4, CA or CAK4
target cells is given. Again both the increase in the MSK4 and CAK4 were statistically significant (P,0.05). Target cells (Hep G2 cells) either mock
treated or pulsed with peptide were utilized as the negative or positive controls.
doi:10.1371/journal.pone.0024477.g005
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degraded in an ubiquitin independent manner [53]. Interestingly,
while this protein has been shown to associate with the ER, its
proteasomal degradation is mediated through direct interaction
with the proteasome a3 subunit.
A remaining question is how the cellular ERAD system
recognizes and dislocates the two forms of misfolded M protein.
Our study shows here that both wild type and misfolded M protein
undergo P97 dependent dislocation and proteasome dependent
degradation. Since Derlin-1, the human homologue of yeast
Der1p, has been shown to be involved in the degradation of other
ERAD substrates through association with P97 to form a channel
like structure facilitating the dislocation process [58,59], it might
be a key factor involved in the degradation of misfolded M protein.
ER chaperones, including BiP, calnexin (CNX), and calreticulin
(CRT) promote folding of ER proteins. However, unsuccessful
cycles of folding or assembly may target these proteins for
retrotranslocation [60]. EDEM accelerates ERAD by extracting
immature monoglucosylated proteins from the CNX-CRT cycle
in a glycan dependent manner [61]. However, our work suggest
that neither Calnexin nor EDEM play a role in the degradation of
the HBV M protein, since the removal of all the N-glycan on M
did not alter its degradation by the proteasome (Figure 3).
It is noted that a recent report has highlighted the importance of
ubiquitination in the degradation of ER associated antigens as
opposed to cytosolic antigens [38]. Our work supports the
hypothesis that ubiquitination is essential for ER associated
antigens, but differs in our work, ubiquitination did not alter the
rate of protein degradation. It is important to note that efficient
antigen presentation of the M protein requires both ubiquitination
and proteasome mediated degradation as proteasome mediated
degradation was not sufficient for antigen presentation (Figure 5).
In conclusion, we report that the HBV envelope protein that
fails ER quality control can enter into the ERAD pathway
independent of ubiquitination. These proteins are subsequently
recognized and efficiently degraded via the cystolic proteasome
complex. The HBV envelope proteins represent one the few
examples of proteins that can efficiently be removed from the ER
and degraded via the proteasome in a ubiquitin independent
manner and by doing so, can limit antigen presentation.
Materials and Methods
HBV M expression constructs
The HBV middle and small surface protein sequences (nt-3174-
1-1980) were derived from subtype ayw (VO1460) through pfu
PCR (Stratagene, La Jolla, CA) amplification and cloned into
pCMV-Tag4A (Stratagene) plasmids by the removal of FLAG and
SV40 polyA sequences from the backbone. This plasmid is
referred to as pCMV-MS. The triple cysteine mutant CA was
made by mutating the triplet codes (TGTs) of Cysteine residues at
positions of 48, 65 and 69 in the S region into GCTs via a joint
PCR method, introducing the substitution of Cysteines to
Alanines. Mutagenesis of Lysine residues (K141, 160) into
Alanines on either the wild type M construct or the CA construct
was performed by using the joint PCR method, and the constructs
were named MSKA and CAKA, respectively. All the constructs
were sequenced for coding fidelity. Using the same mutagenesis
strategy, two arginine residues, R73 and R122, were mutated into
lysines in both the wild type (MS) and the CA mutant and these
vectors are referred to as MSK4 and CAK4. The OVA 257–264
SIINFEKL epitope as placed at the c-terminus of all expression
vectors generating the MSOVA, MSK4OVA, CAOVA and
CAK4OVA constructs. As we have done before, the SIINFEKL
construct was flanked by 4 amino acids on each side to ensure
proper processing and presentation. The entire sequence as
inserted was as follows: SEQLE-SIINFEKL-TEWTS.
OS-9.1, OS-9.2 and EDEM expression vectors
Total cellular RNA from 293T cells was extracted with TRIzol
reagent (Invitrogen). First-strand cDNA was synthesized with
SuperScript III DNA polymerase (Invitrogen) and an oligo(dT)12–
18 primer. Two splicing isoforms OS-9.1 and OS-9.2 were
amplified from HEK293 cells by using the following primers:
GGG AAC GAA AGA TGG CGG CGG AAA CGC T (forward)
and GTT GGT CTC AGA AGT CAA ATT CGT CCA(reverse)
[62]. The purified PCR fragments were cloned into pCDNA3.1/
V5-His-TOPO expression vector (Invitrogen, Carlsbad, CA) and
the cDNAs corresponding to two different splicing isoforms OS-
9.1 and OS-9.2 were verified by sequencing. Since one stop codon
was engineered in the construct upstream of the coding region of
the tags, OS-9 proteins generated from these constructs do not
contain C-terminus tags. EDEM gene was released from full
length expressed sequence tag(Cat# IHS1380-97431075, Open
Biosystems) by SnaBI and NotI digestion and the fragments were
cloned into EcoRV and NotI sites on expression vector
pCDNA3(Invitrogen, Carlsbad, CA). All the constructs were
sequenced for coding fidelity.
Cell culture and plasmid transfection
293T cells [63] were cultured in 6-well plates (Corning,
Corning, NY) with DMEM/F12 medium (Invitrogen, Carlsbad,
CA) containing 10% fetal bovine serum at 37uC with 5% CO2. At
the time when cells reached 90% confluence, Fugene 6 (Roche,
Palo Alto, CA) was used to carry out transfection of plasmid DNA
according to manufacturer’s instruction. Proteasome inhibitor
Lactacystin and epoxomicin (Calbiochem, Gibbstown, NJ) were
dissolved in DMSO and added to the culture medium for 16 h
treatment one day post-transfection at concentrations of 20 uM
and 1.5 uM, respectively.
Antibodies
Polyclonal rabbit antiserum against the HBV PreS2 domain was
purchased from Fitzgerald Industries Intl. (Acton, MA). Anti-HA
(clone 16B12) was purchased from Covance Inc. (Princeton, NJ). A
mouse anti-actin antibody (Chemicon, Temecula, CA) was used for
protein normalization. Rabbit polyclonal anti-VCP (P97) and anti-
OS-9 antibodies were purchased from Novus Biologicals, LLC
(Littleton, CO). Monoclonal Anti-AAT and rabbit polyclonal anti-
EDEM1werepurchasedfromSantaCruzBiotechnologyInc.(Santa
Cruz, CA) and Sigma-Aldrich Inc. (Saint Louis, MO) respectively.
Immunoblotting analysis
Cells in 6-well plates were lysed in 300 mL lysis buffer
containing 50 mM Tris-HCl, pH 7.4, 1 mM EDTA, 0.5% NP-
40 plus fresh 16protease inhibitor cocktail (Sigma, St. Louis, MO)
and 30 mM N-ethylamaleimide (Sigma). Lysates were denatured
in Laemmili buffer and resolved in 12% SDS PAGE gels. For all
samples, protein quantification was performed and proteins loaded
in equal amounts. Proteins were blotted onto PVDF membrane.
After 1 hour blocking, using LI-COR blocking buffer (LI-COR,
Lincoln, Nebraska), primary antibody was applied and incubated
at room temperature (RT) for two hours. In this study, anti-PreS2
and anti-P97 were diluted at 1:1000 blocking buffer. After washing
3 times with PBS+0.1%Tween-20, the membrane was incubated
at RT for 1 hour in blocking buffer containing 1:5000 diluted
IRDye conjugated secondary antibody (LI-COR) corresponding
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washes, the membrane was scanned using the ODYSSEY Infrared
Imaging System (Li-Core) and the signal was quantitatively
analyzed according to manufacturer’s instruction.
HA tagged polyubiquitination assay
An HA-Tagged ubiquitin system previously reported was
utilized to determine the level of protein linked ubiquitin [33].
This system has previously been shown to mimic the level of
ubiquitin conjugation. Briefly, 2 ug HA-ubiquitin expression
vectors were cotransfected with either 3 mg shuttle vectors or
3 mg HBV M expression vectors into 293T cells in a 60 mm
2 dish.
One day post transfection, the cells were treated with proteasome
inhibitor Lactacystin(20 mM) for 16 hours. Thereafter the cells
were lysed in 600 mL 30 mM NEM containing lysis buffer, cell
debris and nuclei were removed by brief centrifugation at 4uC.
250 mL supernatants diluted with 350 mL binding buffer (50 mM
Tris-HCl pH7.4, 150 mM NaCl2, 2 mM EDTA, 0.25% NP40
and 2% BSA) were mixed with 20 ml EZ view HA-tagged affinity
gel (Sigma). After 2 hours rocking at 4uC, the beads were
precipitated and washed 3 times with 800 ml washing buffer of
50 mM Tris-HCl, pH 7.4, 150 mM NaCl2 (500 mM NaCl2 for
the last wash), 5 mM EDTA and 0.5% NP40. The pellet was
desalted with one additional wash with 20 mM Tris-HCl, pH 7.4
and was denatured in 20 ml2 6Laemilli loading buffer.
S
35 labeling and immunoprecipitation
Transfected cells in a 6-well plate were washed with pre-
warmed PBS once and cultured in 1 ml DMEM labeling medium
in absence of methionine and cysteine (Invitrogen) for 30 minutes.
The culture medium was then replaced with 1 ml pre-warmed
DMEM labeling medium containing 100 uCi S
35-methionine/
S
35-cysteine (NEN, NEG072 EXPRE35S35S). After 40 minutes
pulse, cells were chased with regular culture medium at various
time points. Labeled cells were lysed on ice for 30 minutes in
750 ul pre-cold RIPA buffer (50 mM Tris-HCl, pH7.4, 150 mM
NaCl2, 1% Triton X-100, 0.5% sodium deoxycholate, 0.1% SDS
and 16protease inhibitor). Cell debris and nuclei were removed
by brief centrifugation at 4uC and the supernatants were
transferred into a new tube containing 20 mL anti-PreS2 antibody
coated Protein A/G agarose beads (Santa Cruz). After 2 hours
rocking at 4uC, the beads were precipitated and washed 3 times
with 800 uL washing buffer of 50 mM Tris-HCl, pH 7.4,
150 mM NaCl2 (500 mM NaCl2 for the last wash), 5 mM EDTA
and 0.5% NP40. The pellet was desalted with one additional wash
with 20 mM Tris-HCl, pH 7.4 and was denatured in 20 ul 26
Laemilli loading buffer. After electrophoresis in 12% SDS PAGE,
the gel was transferred on PVDF membrane, which was exposed
and quantified by phosphor-image (Bio-Rad, San Francisco, CA).
SIINFEKL Antigen presentation assay
The L-Kb cells were cultured in a 24-well plate. The W/T MS,
MS K4, CA and CAK4 vectors were transfected into mouse L-Kb
cells using with Lipofectamine transfection reagent (Invitrogen)
according to the manufacturer’s directions. After 1 day, the T cell
hybridomas (B3.Z) were added and incubated overnight [44]. The
cells were collected and lysed in 100 ml cell lysis solution
containing 16 protease inhibitors. 5 ml cell lysates were used for
a chemiluminescent reporter assay to measure the level of
b-galactosidase produced by the B3.Z clone. The b-galactosidase
gene allows for easy monitoring of CTL recognition and activation
and the Galacto-Light Plus purchased from Tropix (Bedford, MA).
In Vitro Generation of Peptide-Specific CTLs
Heparinized blood from healthy human leukocyte antigen A2
(HLA-A2) donors was purchased from Research Blood Compo-
nents, LLC (Brighton, MA). Peripheral blood mononuclear cells
(PBMCs) were purified and cultured as described [64,65]. After
initial stimulation with the synthetic HBV peptide FLLTRILTI,
which has been shown to be the major HBV epitope [64,65], T
cells were restimulated with CD4/CD8 T cell–depleted autolo-
gous monocytes pulsed with synthetic peptide at 10 mg/mL for 5
days. Interleukin-2 treatment and in vitro restimulation were
repeated thrice prior to use of in vitro expanded T cells in enzyme-
linked immunosorbent spot (ELISpot) assays. Our previous work
has demonstrated that T cells expanded in this manner secrete
granzyme B and have surface CD8, hallmarks of the cytolytic
potential of CD8+ T cells, so we refer to these cells as CTLs [65].
ELISpot Assays
In vitro–expanded CTLs were used as effectors in ELISpot
assays to assess antigen-stimulated interferon-c release according
to the manufacturer’s instructions (BD-Pharmingen, San Jose,
CA). Target cells were HepG2 human hepatoma cells (HBV
negative; American Type Culture Collection, Manassas, VA)
transfected with 1 mg of either the MS, MSK4, CA, or CAK4
expression vector as targets in ELISpot assays, and were washed
before incubation with T cells. Typically, 2610
5 effectors (T cells)
and 5610
3 targets were used (40:1). Results are presented as
number of interferon c producing cells per 10
6 CD8+ T cells.
Supporting Information
Figure S1 Inhibition of the cytosolic proteasome leads
to the accumulation the HBV p30 M protein species in
HBV producing cell lines. Hep G2.2.15 cells were treated for
16 hours with 1.5 uM epoxomicin and cell lysates examined using
an anti-pre-S2 antibody. As this figure shows, when the
proteasome is inhibited there is an accumulation of several M
protein species, including the p30, gp33 and gp36 forms. As the
HBV L protein also contains the pre-S2 domain, accumulation in
the L protein are also observed following proteasome inhibition.
(TIFF)
Figure S2 HBV M proteins are degraded in a lysosome-
independent but proteasome-dependent manner. In
order to identify the intracellular proteolytic compartments
mediating the degradation of HBV M protein, the pharmacologic
inhibitors chloroquine and epoxomicin, which specifically inhibit
the function of the lysosome and proteasome respectively, were
applied in the medium at the indicated concentration one day
post-transfection. After the overnight treatment, the cells were
lysed and subjected to the western blot using an anti-preS2
antibody. The accumulation of wild type M or the CA mutant
protein occurred in the presence of the proteasome inhibitor only
and implies that the HBV M protein is degraded in a lysosome
independent, but proteasome dependent manner.
(TIFF)
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